Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12 USD | +4.35% | +13.42% | -44.62% |
Financials (USD)
Sales 2024 * | 41.78M | Sales 2025 * | 125M | Capitalization | 722M |
---|---|---|---|---|---|
Net income 2024 * | -394M | Net income 2025 * | -330M | EV / Sales 2024 * | 5.24 x |
Net cash position 2024 * | 503M | Net cash position 2025 * | 330M | EV / Sales 2025 * | 3.13 x |
P/E ratio 2024 * |
-1.85
x | P/E ratio 2025 * |
-2.32
x | Employees | 487 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.53% |
Latest transcript on Sage Therapeutics, Inc.
1 day | +4.35% | ||
1 week | +13.42% | ||
Current month | +8.01% | ||
1 month | +0.08% | ||
3 months | -39.42% | ||
6 months | -43.42% | ||
Current year | -44.62% |
Managers | Title | Age | Since |
---|---|---|---|
Barry Greene
CEO | Chief Executive Officer | 60 | 20-09-30 |
Kimi Iguchi
DFI | Director of Finance/CFO | 61 | 13-02-28 |
Mike Quirk
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeff Jonas
BRD | Director/Board Member | 71 | 13-08-13 |
Barry Greene
CEO | Chief Executive Officer | 60 | 20-09-30 |
Jim Frates
BRD | Director/Board Member | 56 | 14-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.13% | 15 M€ | -2.91% | ||
0.21% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 12 | +4.35% | 1,400,491 |
24-06-13 | 11.5 | +5.99% | 1,653,536 |
24-06-12 | 10.85 | +2.36% | 1,532,715 |
24-06-11 | 10.6 | -2.75% | 3,662,758 |
24-06-10 | 10.9 | +3.02% | 1,458,347 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.62% | 722M | |
+18.15% | 124B | |
+18.02% | 112B | |
-12.75% | 22.22B | |
+5.07% | 22.94B | |
-39.94% | 16.87B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- SAGE Stock